PhD Program in Drug Discovery and Development Industry, College of Pharmacy, Taipei Medical University, Taipei, 11031, Taiwan.
School of Pharmacy, Taipei Medical University, Taipei, 11031, Taiwan.
BMC Cardiovasc Disord. 2021 Feb 8;21(1):77. doi: 10.1186/s12872-021-01893-y.
Patients who receive percutaneous coronary intervention (PCI) have different chances of developing in-stent restenosis (ISR). To date, no predictable biomarker can be applied in the clinic. MicroRNAs (miRNAs or miRs) play critical roles in transcription regulation, and their circulating levels were reported to have potential as clinical biomarkers.
In total, 93 coronary stent-implanted patients without pregnancy, liver or renal dysfunction, malignancy, hemophilia, or autoimmune diseases were recruited in this clinical study. All recruited participants were divided into an ISR group (n = 45) and a non-ISR group (n = 48) based on their restenotic status as confirmed by cardiologists at the first follow-up visit (6 months after surgery). Blood samples of all participants were harvested to measure circulating levels of miRNA candidates (miR-132, miR-142-5p, miR-15b, miR-24-2, and miR-424) to evaluate whether these circulating miRNAs can be applied as predictive biomarkers of ISR.
Our data indicated that circulating levels of miR-142-5p were significantly higher in the ISR population, and results from the receiver operating characteristic (ROC) curve analysis also demonstrated superior discriminatory ability of miR-142-5p in predicting patients' restenotic status. In addition, circulating levels of miR-15b, miR-24-2, and miR-424 had differential expressions in participants with diabetes, hyperlipidemia, and hypertension, respectively.
The current study revealed that the circulating level of miR-142-5p has potential application as a clinical biomarker for predicting the development of ISR in stent-implanted patients.
接受经皮冠状动脉介入治疗（PCI）的患者发生支架内再狭窄（ISR）的机会不同。迄今为止，尚无可预测的生物标志物可应用于临床。微小 RNA（miRNA 或 miRs）在转录调控中发挥关键作用，其循环水平被认为具有作为临床生物标志物的潜力。
本临床研究共招募了 93 名无妊娠、肝肾功能障碍、恶性肿瘤、血友病或自身免疫性疾病的冠状动脉支架植入患者。所有招募的参与者根据心脏病专家在第一次随访（手术后 6 个月）时确认的再狭窄情况分为 ISR 组（n=45）和非 ISR 组（n=48）。采集所有参与者的血样以测量候选 miRNA（miR-132、miR-142-5p、miR-15b、miR-24-2 和 miR-424）的循环水平，以评估这些循环 miRNA 是否可作为 ISR 的预测生物标志物。
我们的数据表明，ISR 人群中 miR-142-5p 的循环水平显著升高，ROC 曲线分析的结果也表明 miR-142-5p 在预测患者再狭窄状态方面具有更好的区分能力。此外，miR-15b、miR-24-2 和 miR-424 的循环水平在患有糖尿病、高脂血症和高血压的参与者中分别存在差异表达。
本研究表明，miR-142-5p 的循环水平具有作为预测支架植入患者 ISR 发展的临床生物标志物的潜力。
